Register now for the 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020), reimagined as a fully virtual event, taking place online over new dates, Nov. 9–14, 2020.
Comprised of several authoritative reviews of checkpoints beyond PD-1, this series, edited by Ana Carrizosa Anderson and Dario A.A. Vignali, promotes the tremendous research that is opening new pathways for treating patients with cancer.
Taught by leading experts in the field, this program, being held virtually Feb. 22–24, provides a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.
The Certificate in Cancer Immunotherapy consists of eight independent learning modules—all approved for CME, CNE, CPE and MOC credits—that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) designation. The SITC-G designation identifies a healthcare provider as completing specialized training in cancer immunotherapy.
The Society for Immunotherapy of Cancer (SITC) is committed to providing the most current COVID-19 information and resources to its members and the oncology community at large.
Join Brianna Hoffner, MSN, ANP-BC, AOCNP, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
New Online Patient Course Available: Understanding Cancer Immunotherapy Access SITC’s dedicated resource for patients and caregivers to learn about cancer immunotherapy
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Purpose: Conversations directly relevant to patient care Audience: Practicing clinicians and staff, clinical investigators Suggested topics: demographics, clinical presentation, diagnostic testing, patient management issues/insights, patterns in ...
Purpose: Conversations directly relevant to research Audience: Laboratory and translational scientists Suggested topics: Data sharing, emerging literature, sample/tissue collection, model/reagent development, opportunities for collaboration, translational ...
I'm delighted to be part of the 2nd edition of this wonderful publication. Since the release of the first edition in 2015 there have been myriad developments in novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org